BioLineRx Ltd. has initiated a first‑in‑human, Phase 1/2a study of its oral small‑molecule candidate GLIX1 for recurrent and progressive glioblastoma and other high‑grade gliomas (NCT07464925). The trial will enroll up to 30 patients and is designed to establish the maximum tolerated dose and gather preliminary safety and efficacy data, with first‑in‑human results expected in the first half of 2027.
GLIX1 targets the DNA damage response pathway through activation of TET2, a mechanism that is unique among glioblastoma therapies. Preclinical models have shown potent anti‑tumor activity and excellent blood‑brain‑barrier penetration, positioning GLIX1 as a promising first‑in‑class candidate in a disease with limited treatment options.
The study will be conducted at three leading academic centers—NYU Langone Health, Northwestern University, and Moffitt Cancer Center—under a joint venture with Hemispherian AS. BioLineRx manages and funds the development, initially holding a 40% stake that can increase to 70% with continued investment, while Hemispherian contributes its DNA damage response expertise.
The glioblastoma market is estimated at $3.7 billion, with 2025 valuations ranging from $3.6 billion to $4.04 billion and projections of $3.8 billion by 2030. BioLineRx’s transition to a lean, royalty‑funded drug developer is reflected in its 2025 financials: revenue fell 95.8% year‑over‑year to $1.2 million, but the net loss improved 78.3% to $2.0 million, and the company holds $20.9 million in cash, sufficient to fund operations into the first half of 2027.
"GLIX1 has a very compelling profile supporting this Phase 1/2a study," said CEO Philip Serlin. Dr. Roger Stupp, lead investigator at Northwestern University, added, "GLIX1 is a promising innovative molecule with impressive pre‑clinical data." Dr. Alexandra Miller of NYU Langone noted, "I am pleased to be the first investigator able to enroll patients into this critical study," while Zeno Albisser of Hemispherian remarked, "This joint venture combines our expertise in DNA damage response research and discovery, with BioLineRx's proven track record of clinical and regulatory success."
The trial’s initiation marks a pivotal moment in BioLineRx’s strategy to focus on drug development. Successful early data could position GLIX1 as a first‑in‑class asset in a sizable market, providing significant upside for the company’s royalty‑funded model and reinforcing its transition away from high‑burn commercial operations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.